Search Result

Results for "

c-Myc Inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	c-Myc (60) Akt (2) Antibiotic (1) Apoptosis (28) Aurora Kinase (2) Autophagy (13) Bacterial (3) Bcl-2 Family (4) Caspase (5) CDK (8) Deubiquitinase (3) DNA/RNA Synthesis (2) E1/E2/E3 Enzyme (1) E3 Ligase Ligand-Linker Conjugates (1) Endogenous Metabolite (1) Epigenetic Reader Domain (17) ERK (1) Fatty Acid Synthase (FASN) (1) Fungal (1) FXR (2) G-quadruplex (2) GSK-3 (1) HDAC (2) Histone Acetyltransferase (2) Histone Methyltransferase (1) HSP (1) HSV (1) Isotope-Labeled Compounds (1) JNK (2) KLF (1) Ligands for Target Protein for PROTAC (1) MAP3K (1) MDM-2/p53 (1) Microtubule/Tubulin (1) Molecular Glues (1) Necroptosis (2) Oct3/4 (1) p38 MAPK (3) Phosphatase (1) PI3K (2) Polo-like Kinase (PLK) (1) Porcupine (1) PPAR (1) PROTACs (4) Ras (1) Reference Standards (2) RET (1) Ser/Thr Kinase (1) Sirtuin (2) STAT (1) Survivin (2) Topoisomerase (1) VEGFR (1) Wnt (5) β-catenin (5)
By Research Areas:	Cancer (89) Cardiovascular Disease (1) Infection (6) Inflammation/Immunology (10) Metabolic Disease (3)

By Targets:

c-Myc (60)

Akt (2)

Antibiotic (1)

Apoptosis (28)

Aurora Kinase (2)

Autophagy (13)

Bacterial (3)

Bcl-2 Family (4)

Caspase (5)

CDK (8)

Deubiquitinase (3)

DNA/RNA Synthesis (2)

E1/E2/E3 Enzyme (1)

E3 Ligase Ligand-Linker Conjugates (1)

Endogenous Metabolite (1)

Epigenetic Reader Domain (17)

ERK (1)

Fatty Acid Synthase (FASN) (1)

Fungal (1)

FXR (2)

G-quadruplex (2)

GSK-3 (1)

HDAC (2)

Histone Acetyltransferase (2)

Histone Methyltransferase (1)

HSP (1)

HSV (1)

Isotope-Labeled Compounds (1)

JNK (2)

KLF (1)

Ligands for Target Protein for PROTAC (1)

MAP3K (1)

MDM-2/p53 (1)

Microtubule/Tubulin (1)

Molecular Glues (1)

Necroptosis (2)

Oct3/4 (1)

p38 MAPK (3)

Phosphatase (1)

PI3K (2)

Polo-like Kinase (PLK) (1)

Porcupine (1)

PPAR (1)

PROTACs (4)

Ras (1)

Reference Standards (2)

RET (1)

Ser/Thr Kinase (1)

Sirtuin (2)

STAT (1)

Survivin (2)

Topoisomerase (1)

VEGFR (1)

Wnt (5)

β-catenin (5)

By Research Areas:

Cancer (89)

Cardiovascular Disease (1)

Infection (6)

Inflammation/Immunology (10)

Metabolic Disease (3)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: c-Myc

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-148836

c-Myc inhibitor 6	c-Myc	Infection Cardiovascular Disease Cancer
c-Myc inhibitor 6 (compound A102) is a *c-Myc* inhibitor. c-Myc inhibitor 6 decreases cancer cell viability and degrades c-Myc protein. c-Myc inhibitor 6 can be used for the research of c-Myc imbalance, such as cancer, cardiovascular diseases, and viral infection .

HY-160549

c-Myc inhibitor 14	c-Myc	Cancer
c-Myc inhibitor 14 (Compound 13A) is a *c-Myc* protein inhibitor. The IC₅₀ value of HL60 inhibitor is <100 nM. c-Myc inhibitor 14 shows antitumor activity .

HY-162294

c-Myc inhibitor 13	c-Myc	Cancer
c-Myc inhibitor 13 (compound A6) is a c-MYC transcription inhibitor. c-Myc inhibitor 13 selectively stabilizes c-MYC G4 and inhibits G4-associated c-MYC transcription .

HY-148838

c-Myc inhibitor 8	c-Myc	Cancer
c-Myc inhibitor 8 (compound 56) is a *c-Myc* inhibitor. c-Myc inhibitor 8 effectively inhibits cell viability of a variety of cancer cells. c-Myc inhibitor 8 inhibits human prostate and lung cancer growth in mouse models. c-Myc inhibitor 8 can be used for cancer research .

HY-148839

c-Myc inhibitor 9	c-Myc	Cancer
c-Myc inhibitor 9 (compound 332) is a *c-Myc* inhibitor with an logEC₅₀ of ≥6. c-Myc inhibitor 9 inhibits tumor growth in nude mouse models. c-Myc inhibitor 9 can be used for cancer research .

HY-155507

c-Myc inhibitor 11	c-Myc	Cancer
c-Myc inhibitor 11 (Compound 67e) is a *c-MYC* inhibitor (pEC₅₀: 6.4). c-Myc inhibitor 11 has high clearance levels, moderate volume of distribution and short half-life in rat pharmacokinetic assay. c-Myc inhibitor 11 can be used for cancer research .

HY-145843

c-Myc inhibitor 5	c-Myc	Cancer
c-Myc inhibitor 5 (DA3) is a fluorescent, long chain-bridged bispurine that selectively targets the c-MYC G-quadruplex (K_D of 16 μM). c-Myc inhibitor 5 shows inhibition on c-MYC expression rather than other G4-driven oncogenes .

HY-169921

c-Myc inhibitor 15	c-Myc Apoptosis	Cancer
c-Myc inhibitor 15 (Compound A5) is a selective *c-Myc* inhibitor that exerts anticancer effects by disrupting the interaction between *c-Myc* and Max, leading to the degradation of *c-Myc* protein and the induction of apoptosis. Its IC₅₀ values are 4.08 μM and 7.86 μM in A549 and NCI-H1299 lung cancer cell lines, respectively, demonstrating strong cytotoxic activity. In a syngeneic tumor model, c-Myc inhibitor 15 exhibited outstanding antitumor efficacy, achieving a tumor growth inhibition rate of 76.4% and significantly reducing *c-Myc* protein expression levels. c-Myc inhibitor 15 holds promise for research related to *c-Myc*-driven lung cancers .

HY-155508

c-Myc inhibitor 12	c-Myc	Cancer
c-Myc inhibitor 12 (compound 67h) is an inhibitor of c-Myc with a pEC₅₀ of 6.4 .

HY-176066A

c-Myc inhibitor 16 iodide	c-Myc Apoptosis	Cancer
c-Myc inhibitor 16 iodide (Compound W11) is a selective c-Myc G-quadruplex (c-Myc G4) inhibitor. c-Myc inhibitor 16 iodide inhibits the transcription and translation of the c-Myc gene, disrupts the tumor cell cycle, arrests cell growth in the G0/G1 phase and activates the mitochondrial apoptosis pathway to induce early apoptosis of cancer cells. c-Myc inhibitor 16 iodide is promising for research of breast cancer .

HY-154839

c-Myc inhibitor 10	c-Myc	Cancer
c-Myc inhibitor 10 (compound 17), a c-Myc inhibitor, exhibits increased cellular potency, consistent with an increase in permeability with methylation of the morpholine nitrogen .

HY-139885

c-Myc inhibitor 4	c-Myc	Cancer
c-Myc inhibitor 4 is a potent, orally bioavailable *c-MYC-reducing* compound.

HY-168685

c-Myc ligand 1	c-Myc Ligands for Target Protein for PROTAC	Cancer
c-Myc ligand 1, a *c-Myc* inhibitor, is a PROTAC target protein ligand (Ligand for Target Protein for PROTAC). c-Myc ligand 1 can be used for synthesis PROTAC c-Myc inhibitor 7 (HY-148837) .

HY-12702

10058-F4 Maximum Cited Publications 45 Publications Verification	c-Myc Autophagy	Cancer
10058-F4 is a *c-Myc* inhibitor that prevents c-Myc-Max dimerization and transactivation of c-Myc target gene expression.

HY-162796

TS-2	Apoptosis G-quadruplex c-Myc	Cancer
TS-2 is a fluorescent ligand of c-Myc G4 with anticancer activity. TS-2 inhibits the growth of cancer cells and induces apoptosis of cancer cells by targeting the *c-MYC* oncogene promoter G4, causing transcriptional repression of the *c-Myc* oncogene .

HY-147973

IZTZ-1	c-Myc Apoptosis	Cancer
IZTZ-1, an imidazole-benzothiazole conjugate, is a c-MYC G4 ligand. IZTZ-1 is able to downregulate the *c-MYC* expression by stabilizing c-MYC G4. IZTZ-1 induces cell cycle arrest, apoptosis, thereby inhibiting cell proliferation in B16 cells. IZTZ-1 shows antitumor activity, and can be used for melanoma research .

HY-124129

10074-A4	c-Myc	Cancer
10074-A4 is a c-Myc inhibitor. 10074-A4 could bind to c-Myc_370-409 at different sites along the peptide chain. 10074-A4 has anticancer effects .

HY-111411

IZCZ-3 2 Publications Verification	c-Myc Autophagy	Cancer
IZCZ-3 is a potent c-MYC transcription inhibitor with antitumor activity .

HY-146445

P300 bromodomain-IN-1	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
P300 bromodomain-IN-1 (Compoun 1u) is a potent p300 (EP300) bromodomain inhibitor with an IC₅₀ of 49 nM. P300 bromodomain-IN-1 suppresses the expression of c-Myc and induces G1/G0 phase arrest and apoptosis in OPM-2 cells .

HY-12703

KSI-3716 2 Publications Verification	c-Myc Autophagy	Cancer
KSI-3716 is a potent *c-Myc* inhibitor that blocks c-MYC/MAX binding to target gene promoters. KSI-3716 is an effective intravesical chemotherapy agent for bladder cancer .

HY-149513

EP12	c-Myc Apoptosis	Cancer
EP12 is a *c-Myc* inhibitor. EP12 is a c-Myc G4 stabilizer. EP12 induces apoptosis and DNA damage in multiple myeloma cells. EP12 disrupts the nuclear translocation of P65/P50 by interfering with the NF-κB signaling pathway. EP12 inhibits multiple myeloma growth .

HY-124811

IRES-C11	c-Myc	Cancer
IRES-C11 is a spectfic c-MYC internal ribosome entry site (IRES) translation inhibitor. IRES-C11 blocks the interaction of a requisite c-MYC IRES trans-acting factor, heterogeneous nuclear ribonucleoprotein A1, with its IRES. IRES-C11 does not inhibits BAG-1, XIAP and p53 IRESes .

HY-156673

m-Se3	c-Myc	Cancer
m-Se3 is a potent and selective *c-MYC* transcription inhibitor that can inhibit tumor growth and has anti-cancer activity .

HY-135691

hnRNPK-IN-1	c-Myc Apoptosis	Cancer
hnRNPK-IN-1 is a heterogeneous nuclear ribonucleoprotein K (hnRNPK) binding ligand with K_d values of 4.6 μM and 2.6 μM measured with SPR and MST, respectively. hnRNPK-IN-1 inhibits c-myc transcription by disrupting the binding of hnRNPK and c-myc promoter. hnRNPK-IN-1 induces Hela cells apoptosis and has strongly anti-tumor activities .

HY-174403

c-MYC/BCL2 ligand 1 iodide	Bcl-2 Family c-Myc Apoptosis Caspase	Cancer
c-MYC/BCL2 ligand 1 iodide is a dual-targeting c-MYC/Bcl-2 G4 ligand with K_d values of 0.90 μM (c-MYC G4) and 0.56 μM (Bcl-2 G4). c-MYC/BCL2 ligand 1 iodide inhibits *c-MYC* and Bcl-2 gene transcription by binding to G4-forming sequences and downregulates their protein expression. c-MYC/BCL2 ligand 1 iodide inhibits suppresses migration, induces caspase-dependent apoptosis, and triggers cell cycle G1 arrest in MCF-7 cells. c-MYC/BCL2 ligand 1 iodide significantly suppresses tumor growth in a 4T1 syngeneic model with no observable toxicity. c-MYC/BCL2 ligand 1 iodide can be used for the research of breast cancer.

HY-175265

PQ32	c-Myc Ras Apoptosis	Cancer
PQ32 is an antitumor agent that targets *c-MYC* Pu27 and KRAS G-quadruplexes. PQ32 inhibits tumor cell proliferation, arrests the cell cycle at the G2 phase, and induces apoptosis. PQ32 inhibits the expression of *c-MYC* and KRAS genes. PQ32 can inhibit tumor growth in mice and is used in the study of lymphoma, breast cancer, lung cancer, hepatocellular carcinoma, colorectal cancer, and other cancers .

HY-162469

6K465	Aurora Kinase c-Myc	Cancer
6K465 is a pyrimidine-based Aurora A (AURKA) inhibitor. 6K465 can reduce the levels of *c-MYC* and N-MYC oncoproteins, demonstrating anticancer activity .

HY-168326

Antiproliferative agent-64	DNA/RNA Synthesis Microtubule/Tubulin	Cancer
Antiproliferative agent-64 (Compound 76) is an inhibitor for eukaryotic translation initiation factor 4E (eIF4E), that block the secondary structure of mRNA, thereby inhibiting protein translation. Antiproliferative agent-64 inhibits the 5' untranslated region (5'UTR) of c-Myc (c-myc 5'UTR) with an EC₅₀ of 1.2 nM, inhibits 5'UTR encoding tubulin (tub 5'UTR) with an EC₅₀ of 40 nM. Antiproliferative agent-64 inhibits the proliferation of MDA-MB-231 with an EC₅₀ of 7 nM .

HY-176488

Y-99	Porcupine Wnt β-catenin c-Myc	Cancer
Y-99 is a PORCN inhibitor with an IC₅₀ of 155.4 nM against the Wnt/β-catenin signaling pathway. Y-99 inhibits the expression of p-LRP6, β-catenin, and *c-Myc* .

HY-100669

Mycro 3 5 Publications Verification	c-Myc Autophagy	Cancer
Mycro 3 is an orally active, potent and selective inhibitor of Myc-associated factor X (MAX) dimerization. Mycro 3 also inhibit DNA binding of c-Myc . Mycro 3 could be used for the research of pancreatic cancer .

HY-147651

β-catenin-IN-4	β-catenin CDK c-Myc	Cancer
β-catenin-IN-4 (Compound 39) is a β-catenin inhibitor with a K_i of 0.64 μM. β-catenin-IN-4 reduces the protein expression levels of cyclin D1 and c-Myc .

HY-168684

E3 Ligase Ligand-linker Conjugate 136	E3 Ligase Ligand-Linker Conjugates	Cancer
E3 Ligase Ligand-linker Conjugate 136 is an E3 ligase ligand-linker conjugate. E3 Ligase Ligand-linker Conjugate 136 can be used to synthesize c-Myc inhibitor 7 (HY-148837) .

HY-134761

EN4 1 Publications Verification	c-Myc	Cancer
EN4 is a covalent ligand that targets cysteine 171 (C171) of MYC. EN4 is selective for *c-MYC* over N-MYC and L-MYC. EN4 inhibits MYC transcriptional activity, downregulates MYC targets, and impairs tumorigenesis .

HY-112316

BAY1238097	Epigenetic Reader Domain	Cancer
BAY1238097 is a potent and selective inhibitor of BET binding to histones and has strong anti-proliferative activity in different AML (acute myeloid leukemia) and MM (multiple myeloma) models through down-regulation of c-Myc levels and its downstream transcriptome (IC₅₀ <100 nM).

HY-163108

ATAD2-IN-1	Epigenetic Reader Domain Apoptosis c-Myc	Cancer
ATAD2-IN-1 (compound 19f) is a potent ATAD2 inhibitor (IC₅₀: 0.27 μM) and can induce apoptosis. ATAD2-IN-1 also inhibits c-Myc activation and BT-549 cell migration .

HY-112799

DK419	Wnt β-catenin c-Myc CDK Survivin	Cancer
DK419 is a potent and orally active Wnt/β-catenin signaling inhibitor, with an IC₅₀ of 0.19 μM. DK419 reduces protein lelvels of Axin2, β-catenin, c-Myc, Cyclin D1 and Survivin and induces production of pAMPK .

HY-124447

BTYNB	c-Myc	Cancer
BTYNB is a potent and selective inhibitor of IMP1 binding to c-Myc mRNA (IC₅₀=5 μM). BTYNB exhibits selectivity and effectiveness against IMP1-postive cancer cell lines. BTYNB can be used for cancer research .

HY-17381A

Idarubicin 10+ Cited Publications 4-Demethoxydaunorubicin	Topoisomerase Bacterial Fungal Autophagy c-Myc DNA/RNA Synthesis Antibiotic	Infection Cancer
Idarubicin is an orally active and potent anthracycline antileukemic agent. Idarubicin inhibits the topoisomerase II interfering with the replication of DNA and RNA transcription. Idarubicin shows induction of DNA damage. Idarubicin inhibits DNA synthesis and of *c-myc* expression. Idarubicin inhibits the growth of bacteria and yeasts .

HY-109050

Alobresib 2 Publications Verification GS-5829	Epigenetic Reader Domain	Cancer
Alobresib (GS-5829) is a BET bromodomain inhibitor, which represents a highly effective therapeutics agent against recurrent/chemotherapy resistant uterine serous carcinoma (USC) overexpressing c-Myc. Alobresib can be used in the metastatic castration-resistant prostate cancer (mCRPC) research .

HY-149451

SYHA1815	RET VEGFR c-Myc	Cancer
SYHA1815 is an orally active RET inhibitor (IC₅₀=0.9 nmol/L) with antitumor activity. SYHA1815 is more selective for RET than KDR (IC₅₀=15.9 nmol/L). SYHA1815 arrests the G1 cell cycle and inhibits RET-driven cell proliferation by downregulating *c-Myc* .

HY-145748

SYUIQ-5	G-quadruplex Autophagy c-Myc	Cancer
SYUIQ-5 is a G-quadruplex ligand. SYUIQ-5 stabilizes G-quadruplex and induce senescence. SYUIQ-5 inhibits *c-myc* gene promoter activity. SYUIQ-5 induces cancer cells autophagy by triggering telomere damage through TRF2 delocalization from telomeres .

HY-155153

CDK9-IN-24	Apoptosis CDK	Others
CDK9-IN-24 (compound 21a) is a highly selective CDK9 inhibitor with significant inhibitory effect on tumor growth. CDK9-IN-24 effectively blocks cell proliferation and induces apoptosis by downregulating Mcl-1 and c-Myc, and can be used in acute myeloid leukemia research .

HY-176142

YX0798	CDK c-Myc Apoptosis Bcl-2 Family	Cancer
YX0798 is a selective and orally active CDK9 inhibitor (K_d: 0.28 nM). YX0798 downregulates the oncoprotein *c-MYC* and pro-survival protein MCL-1. YX0798 disrupts the cell cycle and results in transcriptomic reprogramming, eventually leading to cell apoptosis. YX0798 has antitumor activity .

HY-169348

β-catenin-IN-8	β-catenin Wnt c-Myc	Cancer
β-catenin-IN-8 (Compound 25) is a β-catenin inhibitor. β-catenin-IN-8 inhibits β-catenin and c-Myc protein levels, and inhibits Wnt-target genes level (Fgf20 and Sall4). β-catenin-IN-8 has colorectal cancer anticancer activities, and has metabolic stability .

HY-112316A

(R)-BAY1238097	Epigenetic Reader Domain	Cancer
(R)-BAY1238097 is the R-isomer with lower activity of BAY1238097. BAY1238097 is a potent and selective inhibitor of BET binding to histones and has strong anti-proliferative activity in different AML (acute myeloid leukemia) and MM (multiple myeloma) models through down-regulation of c-Myc levels and its downstream transcriptome .

HY-176347S

Alpha Feto Protein, Arg-13C6,15N4, Lys-13C6,15N2	Isotope-Labeled Compounds	Cancer
Alpha Feto Protein, Arg- ¹³C₃₆, ¹⁵N₄, Lys- ¹³C₆, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled Alpha Feto Protein.

HY-13241

Ralimetinib dimesylate 10+ Cited Publications LY2228820 dimesylate	p38 MAPK Autophagy Apoptosis	Inflammation/Immunology Cancer
Ralimetinib dimesylate (LY2228820 dimesylate) is a selective, ATP-competitive inhibitor of p38 MAPK α/β with IC₅₀s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38a MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc.

HY-162470

DBPR728	Aurora Kinase	Cancer
DBPR728 is an acyl prodrug of 6K465 that carries fewer hydrogen bond donors. 6K465 acts as an Aurora kinase inhibitor that destabilizes MYC family cancer proteins and has antitumor efficacy. DBPR728 has the potential to inhibit cancers that overexpress C-MYC and N-MYC, with a 10-fold increase in oral bioavailability compared to 6K465 .

HY-121917

Ro 31-7837	c-Myc Apoptosis	Inflammation/Immunology
APTO-253 (LOR-253) hydrochloride is a small molecule that inhibits c-Myc expression, stabilizes G-quadruplex DNA, and induces cell cycle arrest and apoptosis in acute myeloid leukemia cells. APTO-253 hydrochloride mediates anticancer activity via induction of Kruppel-like factor 4 (KLF4) tumor suppressor. APTO-253 hydrochloride exhibits antiarthritic activity.

HY-149495

CP-07	PROTACs CDK	Cancer
CP-07 is a potent and selective PROTACCDK9 degrader (DC₅₀: 43 nM). CP-07 inhibits 22RV1 cell proliferation (IC₅₀: 62 nM) and colony formation by down-regulating Mcl-1 and c-Myc. CP-07 inhibits 22RV1 xenograft tumor growth. CP-07 can be used for research of prostate cancer .

Cat. No.	Product Name

HY-L064

Glutamine Metabolism Compound Library

1,353 compounds

Glutamine is an important metabolic fuel that helps rapidly proliferating cells meet the increased demand for ATP, biosynthetic precursors, and reducing agents. Glutamine Metabolism pathway involves the initial deamination of glutamine by glutaminase(GLS), yielding glutamate and ammonia. Glutamate is converted to the TCA cycle intermediate α-ketoglutarate (α-KG) by either glutamate dehydrogenase (GDH) or by the alanine or aspartate transaminases (TAs), to produce both ATP and anabolic carbons for the synthesis of amino acids, nucleotides and lipids. During periods of hypoxia or mitochondrial dysfunction, α-KG can be converted to citrate in a reductive carboxylation reaction catalyzed by IDH2. The newly formed citrate exits the mitochondria where it is used to synthesize fatty acids and amino acids and produce the reducing agent, NADPH.

Cancer cells display an altered metabolic circuitry that is directly regulated by oncogenic mutations and loss of tumor suppressors. Mounting evidence indicates that altered glutamine metabolism in cancer cells has critical roles in supporting macromolecule biosynthesis, regulating signaling pathways, and maintaining redox homeostasis, all of which contribute to cancer cell proliferation and survival. Thus, intervention in glutamine metabolic processes could provide novel approaches to improve cancer treatment.

MCE owns a unique collection of 1,353 compounds targeting the mainly proteins and enzymes involved in glutamine metabolism pathway. Glutamine Metabolism compound library is a useful tool for intervention in glutamine metabolic processes.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0704

Agrimol B 1 Publications Verification	Agrimonia pilosa Ledeb. Structural Classification Classification of Application Fields Rosaceae Phenols Polyphenols Metabolic Disease Plants Disease Research Fields	Sirtuin PPAR Fatty Acid Synthase (FASN) c-Myc Bacterial
Agrimol B, a polyphenol, is an orally active and potent SIRT1 activator. Agrimol B shows anti-adipogenic and anticancer activity. Agrimol B shows antibacterial activity against plant pathogens. Agrimol B dramatically inhibits 3T3-L1 adipocyte differentiation by reducing PPARγ, C/EBPα, FAS, UCP-1, and apoE expression. The action of Agrimol B on the cancer cells is likely derived from its effect on *c-MYC, SKP2* and p27 .

HY-N0330

Momordin Ic 3 Publications Verification	Kochia scoparia L. Schrad. Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Plants Disease Research Fields Chenopodiaceae Cancer	Apoptosis Autophagy PI3K c-Myc
Momordin Ic is an orally active triterpenoid saponin that can be isolated from Kochia scoparia. It is also a SUMO specific protease 1 (SENP1) inhibitor, *SENP1/c-MYC* signaling pathway inhibitor, and apoptosis inducer. Momordin Ic induces autophagy and apoptosis in liver cancer cells through the PI3K/Akt and MAPK signaling pathways mediated by reactive oxygen species. Momordin Ic has the ability to control glucose induced blood glucose elevation, inhibit gastric emptying, resist rheumatoid arthritis, reduce CCl₄ (HY-Y0298) induced hepatotoxicity and anti-tumor activity .

HY-107738

Guggulsterone Maximum Cited Publications 17 Publications Verification Z/E-Guggulsterone	Triterpenes Structural Classification Classification of Application Fields Terpenoids Plants Burseraceae Disease Research Fields Commiphora wightii Cancer	Apoptosis JNK Akt Caspase FXR Autophagy
Guggulsterone is a plant sterol derived from the gum resin of the tree Commiphora wightii. Guggulsterone inhibits the growth of a wide variety of tumor cells and induces apoptosis through down regulation of antiapoptotic gene products (IAP1, xIAP, Bfl-1/A1, Bcl-2, cFLIP and survivin), modulation of cell cycle proteins (cyclin D1 and c-Myc), activation of caspases and JNK, inhibition of Akt . Guggulsterone, a farnesoid X receptor (FXR) antagonist, with IC₅₀s of 24.06 μM and 39.05 μM for (-)-(E)-Guggulsterone (HY-N7781) and (Z)-Guggulsterone (HY-110066), respectively .

HY-N8146

Bruceantinol	Infection Triterpenes Simaroubaceae Classification of Application Fields Brucea antidysenterica J.F.Mill. Terpenoids Source classification Plants Disease Research Fields Brucea javanica (L.) Merr. Cancer	STAT Bcl-2 Family Ser/Thr Kinase Survivin c-Myc Apoptosis Necroptosis CDK
Bruceantinol is a quassinoid that can be isolated from Brucea javanica, inhibits pepper mottle virus (PepMoV) in pepper. Bruceantinol is a STAT3 inhibitor demonstrating potent antitumor activity in in vitro and in vivo human colorectal cancer (CRC) models. Bruceantinol has potent anti-leukemic activity. Bruceantinol strongly inhibits STAT3 DNA-binding ability (IC₅₀ = 2.4 pM), blocks the constitutive and IL-6-induced STAT3 activation, and suppresses transcription of MCL-1, PTTG1, survivin and *c-Myc. Bruceantinol binds with CDK2/4/6* to facilitate protein degradation through proteasome pathway. Bruceantinol can dose- and time-dependently reduces the cell growth, impede cell proliferation, disrupts the cell cycle, and induces necrosis in MCF-7 cells and apoptosis in MDA-MB-231 cells .

HY-N0330R

Momordin Ic (Standard)	Kochia scoparia L. Schrad. Triterpenes Structural Classification Terpenoids Source classification Plants Chenopodiaceae	Reference Standards Apoptosis Autophagy PI3K c-Myc
Momordin Ic (Standard) is the analytical standard of Momordin Ic. This product is intended for research and analytical applications. Momordin Ic is an orally active triterpenoid saponin that can be isolated from Kochia scoparia. It is also a SUMO specific protease 1 (SENP1) inhibitor, SENP1/c-MYC signaling pathway inhibitor, and apoptosis inducer. Momordin Ic induces autophagy and apoptosis in liver cancer cells through the PI3K/Akt and MAPK signaling pathways mediated by reactive oxygen species. Momordin Ic has the ability to control glucose induced blood glucose elevation, inhibit gastric emptying, resist rheumatoid arthritis, reduce CCl4 (HY-Y0298) induced hepatotoxicity and anti-tumor activity .

HY-107738R

Guggulsterone (Standard)	Triterpenes Structural Classification Terpenoids Plants Burseraceae Commiphora wightii	Apoptosis JNK Akt Caspase FXR Autophagy Reference Standards
Guggulsterone (Standard) is the analytical standard of Guggulsterone (HY-107738). This product is intended for research and analytical applications. Guggulsterone is a plant sterol derived from the gum resin of the tree Commiphora wightii. Guggulsterone inhibits the growth of a wide variety of tumor cells and induces apoptosis through down regulation of antiapoptotic gene products (IAP1, xIAP, Bfl-1/A1, Bcl-2, cFLIP and survivin), modulation of cell cycle proteins (cyclin D1 and c-Myc), activation of caspases and JNK, inhibition of Akt. Guggulsterone, a farnesoid X receptor (FXR) antagonist, with IC₅₀s of 24.06 μM and 39.05 μM for (-)-(E)-Guggulsterone (HY-N7781) and (Z)-Guggulsterone (HY-110066), respectively.

Cat. No.	Product Name	Chemical Structure

HY-176347S

Alpha Feto Protein, Arg-13C6,15N4, Lys-13C6,15N2
Alpha Feto Protein, Arg- ¹³C₃₆, ¹⁵N₄, Lys- ¹³C₆, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled Alpha Feto Protein.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks